MET and hemorrhage: The molecular alteration of CDK6, EGFR, and FGFR2 was each associated with shorter overall survival time of patients in both the hemorrhage and non-hemorrhage groups (Fig. 5), and the alteration of CDKN2A/B, FGFR3, MET, MYB, MYBL1, IDH1, and TERT showed prognostic significance in the non-hemorrhage group but displayed no difference in the hemorrhage group (Figure S3).